^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
OncoSignature® Test

Type:
Laboratory Developed Test

Details

Evidence
Twitter
OncoSignature® companion diagnostics that are being developed to be used to identify patients most likely to benefit from Acrivon’s product candidates. Through its highly specific patient selection, the company seeks to accelerate clinical development and increase the probability of successful treatment outcome for patients.
Cancer:
Endometrial Cancer, Ovarian Cancer, Urothelial Cancer
Drug:
prexasertib (ACR-368)
Method:
Akoya’s PhenoImager™ Solution